Somerville, MA, United States of America

Joseph Iacona

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 9.4

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Joseph Iacona in Ocular Treatment

Introduction

Joseph Iacona, an inventor based in Somerville, MA, has made noteworthy contributions in the field of ocular treatments. With a total of two patents to his name, his work focuses primarily on advanced methods and devices for treating retinal diseases using innovative ocular implants.

Latest Patents

Joseph Iacona's latest patents include:

1. **Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor** - This invention outlines methods for treating eye conditions with a sustainable, biodegradable ocular implant that releases a tyrosine kinase inhibitor embedded within a hydrogel.

2. **Ocular implant containing a tyrosine kinase inhibitor** - This patent pertains to a sustained-release biodegradable ocular implant, designed to administer a tyrosine kinase inhibitor for prolonged treatment of retinal diseases.

Career Highlights

Joseph Iacona is currently employed at Ocular Therapeutix, Inc., a prominent company dedicated to advancing ocular therapies through innovative technologies. His dedication to developing effective treatment options positions him as a valuable asset in the field of ophthalmology.

Collaborations

During his career, Joseph has collaborated with notable coworkers such as Charles D Blizzard and Arthur Driscoll. Their combined expertise contributes to the advancement of ocular treatment solutions and fosters innovation within the company.

Conclusion

In summary, Joseph Iacona's work stands at the forefront of ocular treatment innovation. Through his patents and collaborative efforts at Ocular Therapeutix, Inc., he is poised to make a significant impact in the realm of retinal disease management, ultimately benefiting patients and advancing medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…